Virax Biolabs (VRAX) Stock Surges 241% After Exclusive Southeast Asia Supply Deal

TLDR

• Virax Biolabs signed an exclusive supply deal with Fosun Diagnostics covering six Southeast Asian markets
• The deal covers its ImmuneSelect immune profiling product line, used for research purposes
• Initial focus is tuberculosis-related research in Thailand, with rollout planned across the region
• Fosun Diagnostics is part of Fosun Pharma, which reported 2025 revenue of approximately $5.8 billion
• VRAX stock surged over 241% on the news; the company has a current market cap of just $2.53M

Virax Biolabs (VRAX) announced on July 9, 2026, that its UK subsidiary has signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics. The news sent VRAX stock up more than 241% on the day.

Virax Biolabs Group Limited, VRAX

The deal covers the supply of Virax’s ImmuneSelect product line — a research-use-only immune profiling portfolio — across six Southeast Asian markets: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia.

Fosun Diagnostics sits under Fosun Medtech, a division of Fosun Pharma. Fosun Pharma posted 2025 revenue of RMB 41.662 billion, or roughly $5.8 billion, giving Virax a well-resourced distribution partner in the region.

Under the terms of the deal, Virax will supply products including ELISpot assay plates — used to measure cellular immune responses — to Fosun under purchase orders. Pricing includes volume-based tiers.

The agreement kicks off with an immediate product supply structure and targets tuberculosis-related research applications in Thailand first, before expanding across the other five markets.

Exclusivity is tied to agreed minimum purchase and performance thresholds. If those aren’t met, the exclusivity arrangement could be revisited.

The framework also leaves the door open for expansion into additional products, higher-volume supply arrangements, and potential OEM or private-label opportunities down the line.

What Is ImmuneSelect?

ImmuneSelect is Virax’s commercially available research-use-only product line. It is separate from ViraxImmune, the company’s in-development diagnostic platform that is still going through clinical and regulatory development.

The distinction matters. ImmuneSelect is already on the market and generating commercial interest. ViraxImmune is not yet there.

James Foster, Chairman and CEO of Virax Biolabs, called the agreement “a major step forward in the commercial rollout” of the ImmuneSelect platform across Southeast Asia.

Leon Zhang, International Commercial Head for China Domestic Business at Fosun MedTech, said Fosun is evaluating ELISpot-based research applications across the region.

Context on VRAX

Virax Biolabs carries a market cap of just $2.53 million, making it a micro-cap stock. Average daily trading volume sits at around 1.05 million shares.

The most recent analyst rating on VRAX is a Buy, with a price target of $1.00.

The stock’s technical sentiment signal is currently listed as Sell, which stands in contrast to today’s sharp price move.

The jump of over 241% puts the stock firmly in focus, though at this market cap size, moves of this scale on news events are not unusual.

As of July 9, 2026, the supply framework is active and purchase orders can be placed immediately under the agreement.

The post Virax Biolabs (VRAX) Stock Surges 241% After Exclusive Southeast Asia Supply Deal appeared first on CoinCentral.